1. Home
  2. ASM vs URGN Comparison

ASM vs URGN Comparison

Compare ASM & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avino Silver & Gold Mines Ltd. (Canada)

ASM

Avino Silver & Gold Mines Ltd. (Canada)

HOLD

Current Price

$6.23

Market Cap

920.7M

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$23.13

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASM
URGN
Founded
1968
2004
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
920.7M
1.1B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
ASM
URGN
Price
$6.23
$23.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$5.27
$29.50
AVG Volume (30 Days)
5.3M
706.1K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
476.57
N/A
EPS
0.14
N/A
Revenue
$86,065,000.00
$96,516,000.00
Revenue This Year
$38.58
$27.96
Revenue Next Year
$39.81
$123.20
P/E Ratio
$47.58
N/A
Revenue Growth
58.42
8.00
52 Week Low
$0.88
$3.42
52 Week High
$6.98
$30.00

Technical Indicators

Market Signals
Indicator
ASM
URGN
Relative Strength Index (RSI) 53.49 50.73
Support Level $5.73 $20.99
Resistance Level $6.48 $23.81
Average True Range (ATR) 0.38 1.18
MACD -0.08 -0.08
Stochastic Oscillator 38.65 70.16

Price Performance

Historical Comparison
ASM
URGN

About ASM Avino Silver & Gold Mines Ltd. (Canada)

Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: